Dear all, Please find attached the draft table mentioned in Michael’s note below. Kind regards, Emily From: <gnso-newgtld-wg-wt2-bounces@icann.org> on behalf of Michael Flemming <flemming@brightsconsulting.com> Date: Thursday 30 March 2017 at 14:19 To: "gnso-newgtld-wg-wt2@icann.org" <gnso-newgtld-wg-wt2@icann.org> Subject: Re: [Gnso-newgtld-wg-wt2] Agenda for WT2 Meeting 30 March 2017 at 21:00 UTC Dear All, Please find the slides for today's scheduled meeting at 21 UTC. Once again, we will have a slight recap as to how Closed Generics are currently defined/mentioned in the RA. After that we will be moving to look at the Pros and Cons. To do this, we will reference a table that has pulled comments referencing a pro or con. These are pulled from the summary of public comments, so for further details we will look at that as necessary. I look forward to speaking with everyone in 8 hours and 45 minutes. Kind regards, Michael Flemming On Mon, Mar 27, 2017 at 9:36 PM, Michael Flemming <flemming@brightsconsulting.com<mailto:flemming@brightsconsulting.com>> wrote: Dear All, My apologies as the slides are not quite ready. That was a typo. But I will send them once they are ready. Our discussion will be focusing on the pros and cons of Closed Generics and possible harm. Kind regards, Michael Flemming On Mon, Mar 27, 2017 at 9:34 PM, Michael Flemming <flemming@brightsconsulting.com<mailto:flemming@brightsconsulting.com>> wrote: Dear All, This week on 30 March 2017 at 21 UTC we will be continuing our discussion on Closed Generics. Below is the agenda. 1. Welcome 2. SOI 3. Closed Generics 4. AOB Also, I send to everyone the slides that I plan to use for the meeting. I look forward to speaking with everyone and having an exciting conversation! Kind regards, Michael Flemming